Genetic Panel Testing for Malignant Hyperthermia in Japan: Discovery of Novel Variants and Clinical Implications
Genes · 2025
DOI: 10.3390/genes16080944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Hirotsugu Miyoshi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 34-8551, Japan. Hauptthemen laut MEDLINE: Malignant Hyperthermia, Ryanodine Receptor Calcium Release Channel. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research from the Japan Society for the Promotion of Science, Grant-in-Aid.
Abstract (Originalsprache)
Background
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle triggered by certain anesthetic agents. While Ryanodine Receptor 1 (RYR1) and Calcium Voltage-Gated Channel Subunit Alpha1 S (CACNA1S) are well-established susceptibility genes, the complete genetic basis of MH remains unclear, particularly in Asian populations.
Methods
We conducted gene panel testing targeting 24 calcium-related genes in 338 individuals from 247 Japanese families with suspected or confirmed MH. Variants were analyzed on a gene-by-gene basis, and their pathogenicity was assessed using in silico prediction tools. Additionally, patients were classified into subgroups based on the results of the calcium-induced calcium release (CICR) assay and the Clinical Grading Scale (CGS) score.
Results
Candidate pathogenic variants were identified in 118 families (48.2%), including 73 (29.8%) in RYR1, 16 (6.5%) in CACNA1S, and 62 (25.3%) in other genes. Among CICR-positive families, RYR1 and CACNA1S variants were detected in 42.0% and 5.3% of cases, respectively. In individuals with high CGS scores (Ranks 5–6), RYR1 and CACNA1S variants were observed in 56.0% and 12.0%, respectively. Variants in other genes such as STAC3, CASQ1, ATP2A1, ASPH, HRC and TRPV1 were also detected.
Conclusions
Our findings confirm the predominant role of RYR1 and CACNA1S in MH susceptibility in the Japanese population and highlight additional candidate genes that may contribute to the condition. Broader genetic screening and functional validation studies are warranted to further elucidate the polygenic nature of MH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 34-8551, Japan.
ORCID-Profile: Hirotsugu Miyoshi, Keiko Mukaida, Kenshiro Kido, Ayako Sumii, Tsuyoshi Ikeda, Guoqiang Xia, Tomomi Ishii, Satoshi Kamiya, Yasuo M Tsutsumi
Förderung
- Scientific Research from the Japan Society for the Promotion of Science
- Grant-in-Aid
Zitieren
APA
Miyoshi, H., Mukaida, K., Otsuki, S., Kido, K., Sumii, A., Ikeda, T., Xia, G., Noda, Y., Ishii, T., Kamiya, S., Narasaki, S., Niinai, H., & Tsutsumi, Y. M. (2025). Genetic Panel Testing for Malignant Hyperthermia in Japan: Discovery of Novel Variants and Clinical Implications. Genes. https://doi.org/10.3390/genes16080944
Vancouver
Miyoshi H, Mukaida K, Otsuki S, Kido K, Sumii A, Ikeda T, et al. Genetic Panel Testing for Malignant Hyperthermia in Japan: Discovery of Novel Variants and Clinical Implications. Genes. 2025. doi:10.3390/genes16080944
BibTeX
@article{Miyoshi2025,
author = {Miyoshi, Hirotsugu and Mukaida, Keiko and Otsuki, Sachiko and Kido, Kenshiro and Sumii, Ayako and Ikeda, Tsuyoshi and Xia, Guoqiang and Noda, Yuko and Ishii, Tomomi and Kamiya, Satoshi and Narasaki, Soshi and Niinai, Hiroshi and Tsutsumi, Yasuo M},
title = {Genetic Panel Testing for Malignant Hyperthermia in Japan: Discovery of Novel Variants and Clinical Implications},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16080944}
}
EUVIMED